title: Depletion of eosinophil infiltration by anti-IL-5 monoclonal antibody (TRFK-5) accelerates open skin wound epithelial closure.
abstract: Wound healing is critical to the survival of the species after injury. Using hamsters as an experimental model, we have shown that eosinophils infiltrate prominently into skin wounds and that they express transforming growth factor-alpha and -beta 1 mRNAs and proteins. We hypothesized that eosinophils are important in wound healing. As no animal model is genetically deficient in eosinophils, a suitable way to test the hypothesis is to selectively reduce and/or deplete the influx of eosinophils into the wound sites. In this study, we report that anti-interleukin-5 monoclonal antibody (TRFK-5) treatment can deplete eosinophils in cutaneous healing wounds. We found that wound closure by re-epithelialization in the experimental group was 4 days faster than in the control group (P < 0.01). The density of eosinophils in day-9 wounds was significantly lower in the experimental group (P < 0.01). Wound-associated eosinophils in each of the TRFK-5-treated hamsters were depleted to the level comparable to unwounded hamster skin. These results demonstrate that anti-interleukin-5 monoclonal antibody treatment can effectively decrease eosinophil infiltration into hamster cutaneous healing wounds and indicate a role for eosinophils in negatively affecting wound re-epithelialization.
authors.affiliation: Department of Oral Medicine and Diagnostic Sciences, Harvard School of Dental Medicine, Boston, MA 02115, USA.
authors.forename: J
authors.initials: J
authors.lastname: Yang
authors.forename: A
authors.initials: A
authors.lastname: Torio
authors.forename: R B
authors.initials: RB
authors.lastname: Donoff
authors.forename: G T
authors.initials: GT
authors.lastname: Gallagher
authors.forename: R
authors.initials: R
authors.lastname: Egan
authors.forename: P F
authors.initials: PF
authors.lastname: Weller
authors.forename: D T
authors.initials: DT
authors.lastname: Wong
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D006224:Cricetinae; D004804:Eosinophils / Q000166:cytology* / Q000187:drug effects / Q000502:physiology; D004847:Epithelial Cells; D004848:Epithelium / Q000187:drug effects / Q000502:physiology; D007274:Injections, Intraperitoneal; D015848:Interleukin-5 / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology*; D008214:Lymphocytes / Q000166:cytology; D008264:Macrophages / Q000166:cytology; D008297:Male; D008407:Mast Cells / Q000166:cytology; D009504:Neutrophils / Q000166:cytology; D012867:Skin / Q000293:injuries*; D013997:Time Factors; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology*
chemical_list: D000911:Antibodies, Monoclonal; D015848:Interleukin-5